Answers are grounded in this paper and cite their sources.
W e are kicking off this issue with a discussion on how to select patients for different food allergy therapies.The landscape of food allergy has changed tremendously over the past few years, including not only two U.S. Food and Drug Administration approved therapies (oral peanut immunotherapy and omalizumab for the treatment of single and/or multiple food allergies) currently available for individuals with food allergy but many novel treatments in development as well.When selecting patients for therapy, important factors to consider include, at a minimum, eligibility, age, type of food trigger, history of life-threatening reactions, baseline quality of life, and presence of atopic comorbidities. 1 Patients have a say in their choice of therapy and avoidance remains an acceptable strategy for those who choose to do so.Mustafa and Sokol 2 address the efficacy of omalizumab for the management of food allergy, both as monotherapy and in conjunction with oral immunotherapy.Omalizumab is currently approved for the management of immunoglobulin E (IgE) mediated food allergy in individuals Ն1 year of age, after results from the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH) study, 3 which demonstrated that omalizumab increases the threshold dose of multiple food allergens needed to elicit an allergic reaction.However, despite the demonstrated efficacy in food allergy and favorable safety profile, many questions remain, including identifying who is the ideal patient for omalizumab, determining the role of oral food challenges before and during therapy, evaluating food allergy tolerance while
No takes yet. Share an insight, caveat, or question.
Aikaterini Anagnostou (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: